Edgewise Therapeutics filed a Form 8-K with the SEC on July 10, 2026, to provide unaudited pro forma condensed financial information as Exhibit 99.1. The filing covers only Item 9.01, which pertains to financial statements and exhibits. No other events, changes in management, or material transactions were announced in this filing.

View Full Filing (SEC EDGAR)

2026-07-13

Edgewise Therapeutics has completed the sale of its muscular dystrophy program, including the sevasemten compound, to Servier Pharmaceuticals LLC and Les Laboratoires Servier. The deal closed on July 10, 2026, with $1.55 billion in upfront cash and up to $1.1 billion in additional milestone payments, for a total potential consideration of $2.65 billion. This transaction was previously announced in June 2026.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding EDGEWISE THERAPEUTICS INC (EWTX)?

Major stakeholders currently include Orbimed Advisors LLC ($488.8M), Ra Capital Management, L.p. ($328.5M), Paradigm Biocapital Advisors LP ($232.0M). Based on the latest 13F filings, there are a total of 217 tracked investment funds and institutions maintaining positions in EWTX.

What is the overall institutional sentiment toward EWTX recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $703.6M, driven by 103 managers accumulating shares while 92 reduced their exposure.

Which institutions have been selling or reducing their EWTX positions?

In the latest period, 69 funds trimmed their holdings, and 23 managers completely exited their positions. The aggregate reported sell value was $1.2B.

Are there any notable investors adding EWTX to their portfolios?

Yes, buying activity remains notable. 35 institutions opened new positions in {ticker}, and 68 existing holders added to their shares. The total reported buy value for the quarter amounted to $1.1B.